SupplementsExercise

The GLIDE-C digital therapeutic program integrating CGM with personalized lifestyle coaching reduces HbA1c in adults with mildly uncontrolled type 2 diabetes.

In a prospective observational cohort study of 18 adults with T2DM (baseline HbA1c 7.5%-9.5%), the GLIDE-C app-based intervention combining CGM with diet, exercise, and cognitive behavioral therapy led to a mean HbA1c reduction of 0.59% (P=.05) over 60 days. Postprandial glucose decreased by 25.42 mg/dL (P=.06), and time in range increased by 9.98%, with improvements in sleep quality (P=.04).

Last updated: Jul 13, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study.

observational

Saboo B, Sabharwal M, Gharia M, Aswal D, Modi P, Maheshwari T, Parikh J, Saanyal S, Agrawal J · JMIR diabetes (2026)

Participants: N/A
Duration: 60 days
Intervention: GLIDE-C program delivered via the Goodflip mobile app, including a 15-day CGM period, personalized diet, exercise, and cognitive behavioral therapy plans with multidisciplinary coaching.
Outcome: HbA1c change, fasting plasma glucose, postprandial glucose, CGM metrics (time in range), lipid profile, anthropometric indices, quality of life (sleep quality), and behavioral outcomes.
Effect Size: N/A (only mean difference reported: -0.59% HbA1c)
Population: Adults aged ≥18 years with confirmed type 2 diabetes mellitus and baseline HbA1c between 7.5% and 9.5% (mean age 49.45 years, 61.1% male).

Result:

PubMed: 42418692DOI: 10.2196/86651

Mechanism Graph

Continuous glucose monitoring provides real-time glucose data
↓
Personalized diet and exercise plans are adjusted based on CGM data
↓
Cognitive behavioral therapy and coaching support behavior change
↓
Result: Improved glycemic control and quality of life

Limitations

  • ⚠Small sample size (n=18) limits generalizability
  • ⚠Short intervention duration (60 days) may not capture long-term effects
  • ⚠Observational design without a control group precludes causal inference

Frequently Asked Questions

What is the GLIDE-C program?▼

GLIDE-C stands for Glycemic Lifestyle Intervention in Diabetes Empowerment-CGM, an app-based digital therapeutic that integrates continuous glucose monitoring with personalized nutrition, exercise, and cognitive behavioral therapy coaching.

How much did HbA1c decrease in the study?▼

Mean HbA1c decreased by 0.59% from baseline, which was statistically significant (P=.05).

Who was eligible for this study?▼

Adults aged 18 years or older with confirmed type 2 diabetes and baseline HbA1c between 7.5% and 9.5% were included.

What were the main limitations of this research?▼

The study had a small sample size of 18 participants, a short 60-day follow-up, and lacked a control group, making it difficult to attribute improvements solely to the intervention.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Saboo B, Sabharwal M, Gharia M, Aswal D, Modi P, Maheshwari T, Parikh J, Saanyal S, Agrawal J. "App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study.." JMIR diabetes, 2026. PMID: 42418692 DOI: 10.2196/86651
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.